CTC-101

N/A

Report date: 2023/12/07 10:01:54

Base Information

Drug NameCTC-101
Drug Alias NameCTC-101
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanjing Bioheng Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Bioheng Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A